title: Quantification of interstitial fibrosis by image analysis on routine renal biopsy in patients receiving cyclosporine.
abstract: BACKGROUND
  Renal interstitial fibrosis (IF) is the main histopathological feature of chronic allograft injury. IF is currently assessed by semiquantitative analysis, but automatic color image analysis may be more reliable and reproducible. We performed a retrospective analysis to calculate IF on routine renal biopsies performed at 1 year posttransplant.
  
  
  METHODS
  Data were obtained from MO2ART, a prospective multicenter trial in which cyclosporine A dose was adjusted based on C2 level. One-year routine biopsies were assessed from 26 patients from two centers. For each biopsy, a section was analyzed by a program of color segmentation imaging, which automatically extracts green color areas characteristic of IF. Results were expressed as percentage of IF and grade (grade 1: <25%, grade 2: 25-50%, and grade 3: >50%).
  
  
  RESULTS
  Mean IF score was 0.35+/-0.04. Quantitative IF grade 1 was observed in 9 biopsies (34.6%), grade 2 in 12 (46.1%), and grade 3 in 5 (19.2%). Diabetes and cytomegalovirus infection were significantly associated with a higher percentage of IF. There was no correlation between the group of randomization and IF. We found a statistical significant correlation between Banff 05 chronic lesions classification and the IF index (P<0.02). Repeated analysis of variance demonstrated an association between high grade of automated IF and a worsening of creatinine clearance (Modification of Diet in Renal Disease) between 1 and 3 years.
  
  
  CONCLUSIONS
  Automatic quantification of IF on routine renal biopsies at one year posttransplant is predictive of long-term allograft function and may assist early diagnosis of the interstitial lesions of chronic allograft injury.
authors.affiliation: Department of Renal Transplantation, Université Paris 5 -René Descartes, Necker Hospital, Paris, France. audeservais@hotmail.com
authors.forename: Aude
authors.initials: A
authors.lastname: Servais
authors.forename: Vannary
authors.initials: V
authors.lastname: Meas-Yedid
authors.forename: Mathias
authors.initials: M
authors.lastname: Buchler
authors.forename: Emmanuel
authors.initials: E
authors.lastname: Morelon
authors.forename: Jean-Christophe
authors.initials: JC
authors.lastname: Olivo-Marin
authors.forename: Yvon
authors.initials: Y
authors.lastname: Lebranchu
authors.forename: Christophe
authors.initials: C
authors.lastname: Legendre
authors.forename: Eric
authors.initials: E
authors.lastname: Thervet
mesh_terms: D000328:Adult; D001706:Biopsy; D002986:Clinical Trials as Topic; D016572:Cyclosporine / Q000627:therapeutic use*; D006680:HLA Antigens / Q000032:analysis; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007668:Kidney / Q000473:pathology*; D016030:Kidney Transplantation / Q000276:immunology / Q000473:pathology*; D008875:Middle Aged; D013997:Time Factors; D014184:Transplantation, Homologous / Q000276:immunology / Q000473:pathology; D016896:Treatment Outcome
chemical_list: D006680:HLA Antigens; D007166:Immunosuppressive Agents; D016572:Cyclosporine